Sacubitril/valsartan in chronic kidney disease: From pharmacological mechanism to clinical application
| Autor: | Gaosi Xu, Xin Huang, Zhifeng Zhou, Xuexin Cheng, Huang Kuang |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
0301 basic medicine
medicine.medical_specialty Tetrazoles Renal function urologic and male genital diseases Sacubitril 03 medical and health sciences chemistry.chemical_compound 0302 clinical medicine Internal medicine medicine Adverse effect Pharmacology Creatinine business.industry Aminobutyrates Biphenyl Compounds Stroke Volume medicine.disease female genital diseases and pregnancy complications Drug Combinations 030104 developmental biology Valsartan chemistry Heart failure business 030217 neurology & neurosurgery Sacubitril Valsartan medicine.drug Kidney disease |
| Zdroj: | European Journal of Pharmacology. 907:174288 |
| ISSN: | 0014-2999 |
| DOI: | 10.1016/j.ejphar.2021.174288 |
| Popis: | Chronic kidney disease (CKD) is an irreversible, progressive disease characterized by persistent kidney damage, and significantly increased risks of cardiovascular event. However, therapeutic strategies to prevent or slow the progression of CKD remain limited. Sacubitril/valsartan (LCZ696), the representative of the first novel angiotensin receptor-neprilysin inhibitor, has been incorporated into clinical practice guidelines for improving outcomes as a milestone in patients with heart failure. Considering the complex and close relationship between CKD and heart failure, LCZ696 may be beneficial in the treatment of CKD. This review summarizes the pharmacological mechanism and clinical application of LCZ696 in patients with CKD, including its effect on cardiovascular risk and renal outcome, together with potential adverse events. Additionally, due to the influence of serum creatinine and estimated glomerular filtration rate on LCZ696 in patients with heart failure, we also discussed the effects of LCZ696 in patients with advanced CKD and end-stage renal disease. It should be noted that, current clinical studies on LCZ696 are mostly carried out in patients with heart failure, and renal indicators are selected as secondary outcomes. Therefore, more researches should be conducted in patients with CKD alone in the future, to determine the efficacy and safety of LCZ696 in patients with CKD. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect